In 2431 healthy 10–25-year-olds, two doses of MenABCWY vaccine were immunologically non-inferior to two MenB-fHbp doses plus one MenACWY-CRM dose for all five serogroups (MenB composite response difference 9·6%), with similar adverse events (21% vs 20%).
RCTn = 2,431
Ostergaard et al. Immunogenicity and safety of a pentavalent meningococcal MenABCWY vaccine in healthy adolescents and young adults: a phase 3, multicountry, randomised, observer-blinded, active-controlled non-inferiority trial